Cargando…
Detection of atovaquone-proguanil resistance conferring mutations in Plasmodium falciparum cytochrome b gene in Luanda, Angola
BACKGROUND: The fixed dose combination atovaquone-proguanil is a recently introduced antimalarial for treatment and prophylaxis of Plasmodium falciparum malaria. It is highly effective with a good tolerability profile and a convenient prophylactic regimen. Nevertheless, cases of treatment failure ha...
Autores principales: | Pimentel, Sónia, Nogueira, Fátima, Benchimol, Carla, Quinhentos, Vatúsia, Bom, Joana, Varandas, Luís, do Rosário, Virgílio, Bernardino, Luís |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1513587/ https://www.ncbi.nlm.nih.gov/pubmed/16597338 http://dx.doi.org/10.1186/1475-2875-5-30 |
Ejemplares similares
-
Prevalence of pfmdr1, pfcrt, pfdhfr and pfdhps mutations associated with drug resistance, in Luanda, Angola
por: Figueiredo, Paula, et al.
Publicado: (2008) -
Plasmodium falciparum Malaria and Atovaquone-Proguanil Treatment Failure
por: Durand, Rémy, et al.
Publicado: (2008) -
Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
por: Blanshard, Andrew, et al.
Publicado: (2021) -
In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand
por: Khositnithikul, Rommanee, et al.
Publicado: (2008) -
Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil
por: Sutherland, Colin J, et al.
Publicado: (2008)